Skip to main content
. 2023 Nov 2;8:96. Originally published 2023 Feb 22. [Version 2] doi: 10.12688/wellcomeopenres.17995.2

Table 2. Number of index cases and their household contacts with listed vaccine status for each age group (N).

Numbers in brackets show the additional individuals included in the sensitivity analysis (n). There are no index cases younger than 18 years old. BNT162b2, Pfizer-BioNTech mRNA vaccine; ChAdOx1, Oxford AstraZeneca adenovirus vector vaccine.

Status Vaccine Age group
<18
N(n)
18-49
N(n)
50-64
N(n)
65+
N(n)
Case 1 ChAdOx1 0 15 (2) 17 (2) 3 (1)
2 ChAdOx1 0 20 (3) 26 (4) 1
1 BNT162b2 0 22 (1) 13 (2) 2
2 BNT162b2 0 13 17 1
None 0 33 12 (1) 0
Contact 1 ChAdOx1 0 (1) 13 (2) 22 (2) 5
2 ChAdOx1 0 13 (2) 22 (2) 3 (1)
1 BNT162b2 0 22 (2) 9 2 (1)
2 BNT162b2 0 14 (1) 16 3
None 67 (7) 55 (8) 11 (2) 1 (1)